Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T13:25:29.371Z.
Calculation as of: 2026-10-06T13:25:29.371Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 83c64da899843448fde498cf5e629ee28b7cf55c7878198a0aebccb75d14602d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Aspire Biopharma Holdings, Inc.
Market Cap
$1.02M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.14M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$885939.00
EV/EBIT Ratio
N/A
TTM Avg
1487.85x
3Y Avg
7742.21x
5Y Avg
7742.21x
Market Cap
$878396.00
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$787624.00
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | $1.02M | N/A | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.11M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.14M | N/A | N/A | N/A | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $888387.00 | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $885939.00 | N/A | 1487.85x | 7742.21x | 7742.21x |
| Bone Biologics Corporation (BBLG)vs › | $878396.00 | N/A | N/A | N/A | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | N/A | 10.71x | 10.71x | 10.71x |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.17M | N/A | N/A | N/A | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $787624.00 | N/A | N/A | N/A | N/A |
| CDT Equity Inc. (CDT)vs › | $707297.00 | 5.81x | 18.06x | 18.06x | 18.06x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
